Table 2.
Demographic and Clinical Characteristics of IBD Patients in Group 2
| Week 28 | Week 52 | |||
|---|---|---|---|---|
| Responders | Non-Responders | Responders | Non-Responders | |
| Number, n | 53 | 9 | 42 | 20 |
| CD, n (%) | 50 (94.3) | 6 (66.7) | 39 (92.9) | 17 (85) |
| Female, n (%) | 20 (37.7) | 3 (33.3) | 17 (40.5) | 6 (30) |
| Age, y | 36 (26–47) | 29 (19–33.5) | 34.5 (24.8–43.3) | 33.5 (24–47.3) |
| Disease duration, y | 1 (0–3) | 1 (0–4) | 1 (0–3) | 0.5 (0–4) |
| BMI, kg/m2 | 19.2 (18.1–21.2) | 17.4 (16.5–19.3) | 19.5 (18.1–21.4) | 18.3 (16.7–20.5) |
| Smoking, n (%) | ||||
| Never smoker | 48 (90.6) | 8 (88.9) | 39 (92.9) | 17 (85) |
| Ex-smoker | 1 (1.9) | 1 (11.1) | 0 (0) | 2 (10) |
| Current smoker | 4 (7.5) | 0 (0) | 3 (7.1) | 1 (5) |
| Drinking, n (%) | ||||
| Never drink | 50 (94.3) | 8 (88.9) | 40 (95.2) | 18 (90) |
| Ex-drink | 0 (0) | 1 (11.1) | 0 (0) | 1 (5) |
| Current drink | 3 (5.7) | 0 (0) | 2 (4.8) | 1 (5) |
| Family history, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Perianal lesions, n (%) | 30 (56.6) | 2 (22.2) | 26 (61.9) | 9 (45) |
| Extraintestinal manifestation, n (%) | 10 (18.9) | 2 (22.2) | 9 (21.4) | 3 (15) |
| Perianal surgery, n (%) | 13 (24.5) | 2 (22.2) | 11 (26.2) | 4 (20) |
| Bowel surgery, n (%) | 13 (24.5) | 1 (11.1) | 9 (21.4) | 5 (25) |
| Medication, n (%) | ||||
| 5-aminosalicylic acid | 33 (62.3) | 5 (55.6) | 27 (64.3) | 11 (55) |
| Corticosteroids | 21 (39.6) | 7 (77.8) | 17 (40.5) | 11 (55) |
| Azathioprine/6-mercaptopurine | 18 (34) | 5 (55.6) | 17 (40.5) | 6 (30) |
| Methotrexate | 7 (13.2) | 2 (22.2) | 5 (11.9) | 4 (20) |
| Thalidomide | 4 (7.5) | 1 (11.1) | 4 (9.5) | 1 (5) |
| Adalimumab | 0 (0) | 1 (11.1) | 0 (0) | 1 (5) |